Acertis Pharmaceuticals Licenses U.S. Commercial Rights to Licart® from IBSA
Expands Pain Management Portfolio with Next-Generation Topical NSAID Therapy RALEIGH, N.C. — January 5, 2026 — Acertis Pharmaceuticals, a specialty pharmaceutical company focused on delivering differentiated therapies to patients, today announced that it has entered into an exclusive agreement with Swiss pharmaceutical company IBSA InstitutBiochimique SA to license the U.S. commercial rights for Licart® (diclofenac […]